The generation of cardiomyocytes from human induced pluripotent stem cells (hiPSCs) provides a source of cells that accurately recapitulate the human cardiac pathophysiology. The application of these cells allows for modeling of cardiovascular diseases, providing a novel understanding of human disease mechanisms and assessment of therapies. Here, we describe a stepwise protocol developed in our laboratory for the generation of hiPSCs from patients with a specific disease phenotype, long-term hiPSC culture and cryopreservation, differentiation of hiPSCs to cardiomyocytes, and assessment of disease phenotypes. Our protocol combines a number of innovative tools that include a codon-optimized mini intronic plasmid (CoMiP), chemically defined culture conditions to achieve high efficiencies of reprogramming and differentiation, and calcium imaging for assessment of cardiomyocyte phenotypes. Thus, this protocol provides a complete guide to use a patient cohort on a testable cardiomyocyte platform for pharmacological drug assessment.
CITATION STYLE
Burridge, P. W., Diecke, S., Matsa, E., Sharma, A., Wu, H., & Wu, J. C. (2014). Modeling cardiovascular diseases with patient-specific human pluripotent stem cell-derived cardiomyocytes. In Methods in Molecular Biology (Vol. 1353, pp. 119–130). Humana Press Inc. https://doi.org/10.1007/7651_2015_196
Mendeley helps you to discover research relevant for your work.